Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Haluk Aydin

Child & Adolescent Psychiatry Petersburg, VA Medical Doctor

NPI 1700857836 CMS profile 468876

269 Medical Park Blvd, Petersburg, VA 23805

Open in the dashboard

General payments

$2,237

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Haluk Aydin of Petersburg, VA is reported in the CMS Open Payments database as having received $2,237 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $514 5
2023 General $67 3
2022 General $24 1
2021 General $111 8
2020 General $576 42
2019 General $945 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Haluk Aydin
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Haluk Aydin were reported at $514. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Haluk Aydin Child & Adolescent Psychiatry median Middle half National median
2019 $945 $129 $42–$419 $163
2020 $576 $81 $28–$226 $114
2021 $111 $115 $31–$326 $132
2022 $24 $124 $40–$382 $149
2023 $67 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $514 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $602 54 payments
  2. E.R. Squibb & Sons, L.L.C. $378 3 payments
  3. Teva Pharmaceuticals USA, Inc. $267 10 payments
  4. Alkermes, Inc. $171 9 payments
  5. Janssen Pharmaceuticals, Inc $167 9 payments
  6. Lundbeck LLC $166 9 payments
  7. Otsuka America Pharmaceutical, Inc. $143 9 payments
  8. Neurocrine Biosciences, Inc. $141 8 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $111 7 payments
  10. Shire North American Group Inc $26 2 payments
  11. Other $64 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,230 123 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. LATUDA $602 54 payments
  2. COBENFY $378 3 payments
  3. ABILIFY MAINTENA $202 11 payments
  4. ARISTADA Cns $156 8 payments
  5. ARISTADA Cns $156 8 payments
  6. ARISTADA Cns $156 8 payments
  7. ARISTADA Cns $156 8 payments
  8. AUSTEDO $146 9 payments
  9. ARISTADA INITIO $134 7 payments
  10. INVEGA SUSTENNA $132 7 payments
  11. Other $885 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,505

Median for Psychiatry: 574

Drug cost

$151,415

Median for Psychiatry: $27,624

Branded share of claims

15.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Maintena Aripiprazole Brand 23 $66,180
Invega Sustenna Paliperidone Palmitate Brand 17 $44,289
Lurasidone Hcl Generic 61 $6,083
Paliperidone Er Paliperidone Brand 14 $4,526
Ziprasidone Hcl Generic 67 $3,468
Aripiprazole Generic 51 $3,160
Quetiapine Fumarate Generic 236 $2,577
Olanzapine Generic 116 $2,513
Divalproex Sodium Er Divalproex Sodium Brand 57 $2,219
Duloxetine Hcl Generic 70 $1,931

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$5,789

Medicare's payments for the services billed

Medicare patients

52

Average age 58

Services billed

117

29 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Depression 71%
Arthritis 46%
Diabetes 40%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record